SEC Comment Letter 0000000000-24-004168 to ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC.
Date: April 17, 2024 · CIK: 0001513525 · Accession: 0000000000-24-004168
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278652
Letter
United States securities and exchange commission logo April 17, 2024 Cary Claiborne Chief Executive Officer Adial Pharmaceuticals, Inc. 4870 Sadler Road, Suite 300 Glen Allen, VA 23060 Re:Adial Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed April 12, 2024 File No. 333-278652 Dear Cary Claiborne: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Hank Gracin
Show Raw Text
United States securities and exchange commission logo
April 17, 2024
Cary Claiborne
Chief Executive Officer
Adial Pharmaceuticals, Inc.
4870 Sadler Road, Suite 300
Glen Allen, VA 23060
Re:Adial Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed April 12, 2024
File No. 333-278652
Dear Cary Claiborne:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Hank Gracin